Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of a Phase III clinical trial for Nilotinib as a first-line treatment for Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharmaceutical-B (02595) initiated a registration clinical trial for GFH375, the world's first oral KRAS G12D inhibitor in a controlled chemotherapy Phase III study [1] - Xixiangfeng Group (02473) signed a business cooperation agreement with Hello Car Rental to develop car rental services in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for a GLP-1/GIP receptor dual agonist injection [1] - MIRXES-B (02629) plans to collaborate with Crystal Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automobile (01728) intends to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) plans to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) successfully included seven innovative products (including new indications) in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biotech-B (09887) presented clinical data for LBL-034 at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Acid Vovizili Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) successfully included five new products in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) had its core products included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported a contract sales amount of approximately 47.7 billion yuan for the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported an equity power generation of 697.23 GWh in November, a year-on-year increase of 7.77% [2]

Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy in first-line treatment of gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of the III phase clinical study of Nilotinib in first-line treatment of Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharma-B (02595) initiated a registration clinical trial for GFH375 in metastatic pancreatic cancer, marking the first global oral KRAS G12D inhibitor monotherapy controlled chemotherapy III phase study [1] - Xixiangfeng Group (02473) subsidiary signed a business cooperation agreement with Hello Car Rental to develop car rental business in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for GLP-1/GIP receptor dual agonist peptide injection [1] - MIRXES-B (02629) plans to collaborate with Jingtai Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automotive (01728) plans to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) intends to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) announced that seven innovative products, including new indications, were successfully included in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biopharma-B (09887) clinical data for LBL-034 was presented at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Aurantium Extract Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) had five new products successfully included in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) core products were included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported contract sales of approximately 47.7 billion yuan in the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported November equity power generation of 697.23 GWh, a year-on-year increase of 7.77% [2]

中经记者 陈家运 北京报道 12月6日，川能动力（000155.SZ）公告人事变动，聘任李金生为总经理，并提名为非独立董事候选人。 原副董事长、总经理万鹏因工作变动辞职，不再担任公司任何职务。 这是川能动力年内第二次核心管理层变动。今年5月，张忠武已接替何连俊担任公司董事长。 川能动力主营业务包括新能源发电和锂电业务。截至12月5日，公司市值214亿元。2025年前三季度，川 能动力实现营业收入20.95亿元，同比下降7.98%；归属于上市公司股东的净利润3.47亿元，同比下滑 44.83%。 （编辑：董曙光 审核：吴可仲 校对：颜京宁） 公告显示，李金生拥有研究生学历及工程师、经济师资质，历任四川省能源投资集团经营管理部副部 长、资产运营管理部副部长，并兼任多家子公司董事，现任四川省新能源动力股份有限公司总经理，四 川能投锂业有限公司党支部委员、董事、总经理。 ...

本报讯 （记者袁传玺）天眼查App显示，近日，中煤（广南）新能源有限公司成立，注册资本3亿元， 经营范围为发电业务、输电业务、供（配）电业务，建设工程监理。股权全景穿透图显示，该公司由中 煤绿能科技（北京）有限公司全资持股，后者为中国中煤能源（601898）集团有限公司全资子公司。 ...

Core Viewpoint - The company reported a year-on-year increase in equity power generation for November 2025, indicating positive growth in its operational performance [1] Group 1: Company Performance - The equity power generation for November 2025 reached 697.23 GWh, representing a 7.77% increase compared to the same month in the previous year [1] - The total equity power generation for the first eleven months of 2025 amounted to 7795.65 GWh [1]

协合新能源(00182)公布，该集团2025年11月权益发电量为697.23GWh，同比增长7.77%。前11个月权益 发电量为7795.65GWh。 ...

Group 1 - The core point of the article is that Xiehe New Energy (00182.HK) reported its equity power generation for November 2025, which totaled 697.23 GWh, representing a year-on-year increase of 7.77% [1] - The solar equity power generation for the same period was 79.01 GWh, showing a significant year-on-year growth of 25.08% [1]

Core Viewpoint - The company, Xiehe New Energy (00182.HK), reported a 7.77% year-on-year increase in equity power generation for November 2025, reaching 697.23 GWh, with a total of 7795.65 GWh for the first 11 months of the year [1] Group 1 - The equity power generation for November 2025 was 697.23 GWh, reflecting a growth of 7.77% compared to the previous year [1] - The total equity power generation for the first 11 months of 2025 amounted to 7795.65 GWh [1]

Group 1 - China's manufacturing industry plays a crucial role in promoting new industrialization, with its manufacturing value-added accounting for nearly 30% of the global total and maintaining the world's largest scale for 15 consecutive years [1] - In 2024, 178 national high-tech zones are expected to contribute 14.3% to the national GDP, gathering 33% of the country's high-tech enterprises and 46% of specialized "little giant" enterprises [1] Group 2 - The development of green electricity parks is essential for the carbon neutrality process, supported by international policies and technological advancements [2] - Since 2010, the average cost of electricity from photovoltaic and onshore wind power has decreased by approximately 90% and 70%, respectively, indicating a significant economic benefit for green electricity parks [2] Group 3 - China has a high dependence on foreign oil and gas resources, with dependency rates of about 72% for crude oil and 38% for natural gas, making the transition to a renewable energy-dominated "electrification era" a strategic choice [3] - By 2024, China's global market share in polysilicon, silicon wafers, battery cells, and modules is projected to reach 93.2%, 96.6%, 92.3%, and 86.4%, respectively, showcasing its strong competitive edge in green electricity manufacturing [3] Group 4 - Financial services are essential for the development of industrial parks, transitioning from optional to necessary, with a focus on fundraising, risk diversification, and resource allocation [4] - Financial institutions can facilitate the transformation of capital expenditures into operational expenditures, helping operators initiate projects with lower capital [4] Group 5 - Various financing tools are available for green electricity park construction, including loans, bonds, equity financing, and innovative models [6] - Public finance tools and bank loans are primary funding sources for construction projects, while equity financing tools like park equity funds are gaining importance [6][7] Group 6 - Financial institutions should provide comprehensive services throughout the lifecycle of industrial parks, addressing different financial needs at various stages, from planning to operation [8][9] - In the operational phase, financial products like REITs and ABS can be utilized to support ongoing development [9] Group 7 - The dual approach of "financing" and "intelligence" is crucial for creating a comprehensive service system that supports both funding and value creation [11][12] - Financial institutions can leverage their expertise in value discovery and cultivation to become true "industry investment banks" and "patient capital" [12] Group 8 - Financial innovation should focus on "one park, one policy" strategies tailored to the unique characteristics of different industrial parks, addressing specific development challenges [15] - This approach aims to match financial supply with rapidly evolving industrial demands, fostering a virtuous cycle of industrial and financial growth [15][16]

新华财经北京12月5日电（记者王悦阳）"十五五"规划建议提出，"持续提高新能源供给比重""着力构建 新型电力系统，建设能源强国"。回望"十四五"，我国逐光驭风、向"绿"而行，全社会用电量中，每3度 电就有1度绿电。 "十四五"是我国能源绿色低碳转型最快的五年。如果把五年间全国新增的光伏板铺展开，总面积可以覆 盖53万座足球场；把新增的风机叶片依次连接，长度相当于从中国最东端到最西端走一个来回。 看发电侧，绿电正从曾经荒无人烟的"沙戈荒"出发，横跨千里，实现"闪送"。 生活中，"开绿车、用绿电"成为越来越多人的选择。截至今年10月底，我国电动汽车充电基础设施总数 达1864.5万个，同比增长54%。 当前，北方地区已进入供暖季。在内蒙古兴安盟科右前旗大坝沟小学，教室内暖意融融，师生们告别了 煤炉取暖的"煤烟味"。今年以来，当地27所中小学校完成清洁能源供暖改造。 工厂里，绿电为产业升级注入新活力。例如，惠达卫浴股份有限公司2024年消费绿电2560万千瓦时，折 合节约3146.24吨标准煤，减排二氧化碳8463.39吨。"使用绿电有助于满足国外客户的环保要求，突破贸 易壁垒。"惠达卫浴设备能源动力部副部长侯鑫说 ...